6 research outputs found
The Evolving Landscape of Lung Cancer Surgical Resection: An Update for Radiologists With Focus on Key Chest CT Findings
Evolution of the multimodality management of early lung cancer, including progress in surgical techniques, has introduced the possibility of resection for lung cancer cases that historically were considered unresectable (e.g., select cases of T4 disease and oligometastatic disease). However, the TNM classification does not uniformly correlate with lung cancer operability and resectability. Radiologic evaluation is therefore critical in identifying patients' suitability to undergo lung cancer resection and in guiding the selection of a surgical approach from among a range of such approaches, including wedge resection, segmentectomy, lobectomy, bilobectomy, and pneumonectomy. The radiologist must understand the available surgical options, along with their advantages and disadvantages, and provide a report that includes critical information on tumor size, location, and extension and anatomic relations that may influence the surgical technique. Preoperative CT findings may also help predict expected postoperative lung function and the associated impact on the postoperative course of the patient. This article reviews the role of chest CT in the preoperative evaluation of lung cancer, focusing on the key CT findings that help direct surgical decision making in the context of an expanding range of patients who may be considered candidates for resection. © 2022 American Roentgen Ray Society. All rights reserved
Predictors of future exacerbation risk in patients with asthma
Objectives: Although modern treatment of asthma improves asthma control, some patients still experience exacerbations. The aim of the present study was to detect predictors of asthmatic exacerbations Methods: We included patients with asthma followed up in asthma clinics of 2 tertiary University hospitals. Demographic and functional characteristics, levels of exhaled NO, and inflammatory biomarkers (IL-13, ΕCP και IL-8) and cell counts in induced sputum were recorded at baseline. Measurements were performed with the patients in stability and were considered as their personal best. Patients received optimal treatment with good compliance and were followed up for 1 year for asthma exacerbations occurrence. Evaluation of the effect of recorded parameters on asthma exacerbations was performed with univariate and multivariate Poisson regression analysis. Results: 171 patients (118 female) with bronchial asthma (mean age 51.6 ± 13.2 years) were included in the study. The mean number of exacerbations in 1 year of follow up was 0.4 ± 0.8 while the majority of patients (71.9%) did not experience any exacerbation. In multivariate Poisson Regression analysis only 3 characteristics were predictors of future exacerbations: FEV1 [IRR(95% CI)], [0.970(0.954–0.987)], p = 0.001, high BMI [1.078(1.030–1.129)], p = 0.001, and the need for permanent treatment with oral corticosteroids for asthma control maintenance [2.542(1.083–5.964)], p = 0.032 Conclusion: Optimal guideline-based asthma management results in minimal occurrence of exacerbations in the majority of patients. Predictors of exacerbations are low FEV1 levels in stability, high BMI and the need for permanent treatment with oral corticosteroids. © 2016 Informa UK Limited, trading as Taylor & Francis Group
Sputum interleukin-13 as a biomarker for the evaluation of asthma control
BackgroundAsthma control refers to the extent to which the
manifestations of asthma have been reduced or eradicated by treatment.
Interleukin-13 (IL-13) has a central role in Th2 response and serves as
a possible therapeutic target in uncontrolled asthma. Fraction of
exhaled nitric oxide (FeNO) and sputum eosinophils have modest
performance in the evaluation of asthma control.
ObjectiveTo assess the diagnostic performance of sputum IL-13 for the
evaluation of asthma control and furthermore to investigate the
performance of sputum eosinophils and FeNO.
MethodsOne hundred and seventy patients with asthma were studied. All
subjects underwent assessment of asthma control by asthma control test
(ACT), lung function tests, FeNO measurement and sputum induction for
cell count identification and IL-13 measurement in supernatants.
ResultsIL-13 (pg/mL) levels in sputum supernatant differed significantly
among patients with well-controlled asthma and those with not
well-controlled asthma [median IQR 78 (66-102) vs. 213 (180-265), P <
0.001]. Receiver operating characteristic (ROC) analysis showed that,
for the whole study population, the diagnostic performance of IL-13 was
superior to both sputum eosinophils and FeNO levels [area under the
curve (AUC) 0.92, 95% CI 0.87 to 0.95 vs. AUC 0.65, 95% CI 0.58 to
0.72 vs. AUC 0.65, 95% CI 0.55 to 0.72, respectively].
ConclusionThe diagnostic performance of sputum IL-13 was superior to
both sputum eosinophils and FeNO levels for the identification of
well-controlled asthma. Sputum IL-13 levels could serve as a useful
biomarker for asthma control assessment